April 2024

NEWS & COLUMNS

6-7 NEWS
AstraZeneca acquires Amolyt for $1.05bn; Pfizer’s antibiotic combination recommended by CHMP

8-9 NEWS
BMS shares positive results for Zeposia in MS; US drugmakers submit drug pricing counter-offers

10-11 DERMATOLOGY NEWS
Sanofi’s results in atopic dermatitis; UCB’s Bimzelx recommended by CHMP

12 DARWIN'S MEDICINE
Strategising fast and slow

13 POLICY AND PUBLIC HEALTH
The princess, the queen and the grandfather

14 THINKING DIFFERENTLY
Exploring the benefits of welcoming neurodiversity in healthcare comms

15 INNOVATIVE IMPACT BLOG
The importance of putting boldness front and centre

FEATURES

16-17 CURRENT TRENDS AND THE RENAISSANCE OF ALZHEIMER’S DRUG DEVELOPMENT
The race is on to find a treatment to not only slow its course, but even prevent the development of the disease

18-19 WOMEN’S HEALTH – MANAGING THE MENOPAUSE
PME spoke to Astellas' Marci English about the importance of new treatments for menopause symptoms, the unmet need and the company’s commitment to midlife women’s health

20-21 IS THE GUT MICROBIOME THE NEXT FRONTIER IN MEDICINE?
Research has long shown a strong connection between disease and the gut microbiome

22-24 RARE DISEASES – RAISING AWARENESS, LISTENING TO PATIENTS, MAKING A DIFFERENCE
PME speaks to Clinigen's Lorna Pender about the treatment options available to patients with rare diseases and the barriers that are hindering access

16. The renaissance of Alzheimer’s drug development